cholesterol

ACC 2023 – Esperion’s outcomes win looks lacklustre
ACC 2023 – Esperion’s outcomes win looks lacklustre
EP Vantage
Esperion Therapeutics
ACC
Nexletol
cholesterol
Flag link:
Abionyx hails success of bid to resurrect failed cholesterol drug—without dishing data to back up claims
Abionyx hails success of bid to resurrect failed cholesterol drug—without dishing data to back up claims
Fierce Biotech
Abionyx
clinical trials
cholesterol
CER-001
Flag link:
AstraZeneca dumps Ionis drug despite hit in phase 2 cholesterol trial
AstraZeneca dumps Ionis drug despite hit in phase 2 cholesterol trial
Fierce Biotech
AstraZeneca
Ionis Pharmaceuticals
clinical trials
ION449
cholesterol
Flag link:
Drugmakers leap back into fading heart drug market
Drugmakers leap back into fading heart drug market
Beckers Hospital Review
Bristol Myers Squibb
Novartis
Merck
Alnylam Pharmaceuticals
Amgen
hypertension
cholesterol
Flag link:
ACC 2022 – Astra’s cholesterol lowerer surprise comes just a little late
ACC 2022 – Astra’s cholesterol lowerer surprise comes just a little late
EP Vantage
AstraZeneca
Ionis Pharmaceuticals
AZD8233
cholesterol
ACC
Amgen
Sanofi
Novartis
Regeneron
Flag link:
Can A New Cholesterol Drug Restore Merck’s Prominence In Heart Drugs?
Can A New Cholesterol Drug Restore Merck’s Prominence In Heart Drugs?
Forbes
Merck
cholesterol
PCSK9 inhibitors
MK-0616
Zocor
Flag link:
Pfizer ends $3B drug dream despite phase 2b success, leaving Regeneron with a clear run at cardiovascular market
Pfizer ends $3B drug dream despite phase 2b success, leaving Regeneron with a clear run at cardiovascular market
Fierce Biotech
Pfizer
vupanorsen
Ionis Pharmaceuticals
cholesterol
Flag link:
It Was To Be The Cholesterol Drug For The Masses. Novartis Changed That.
It Was To Be The Cholesterol Drug For The Masses. Novartis Changed That.
Forbes
Novartis
inclisiran
Leqvio
cholesterol
Flag link:
Novartis wins FDA approval for new heart drug, but faces uphill sales battle
Novartis wins FDA approval for new heart drug, but faces uphill sales battle
BioPharma Dive
Novartis
FDA
Leqvio
cholesterol
Flag link:
Novartis finalizes deal to make new heart drug widely available in England
Novartis finalizes deal to make new heart drug widely available in England
BioPharma Dive
UK
Novartis
Leqvio
heart disease
cholesterol
Flag link:
What if a pill could lower cholesterol like pricey injectables? Esperion intends to find out
What if a pill could lower cholesterol like pricey injectables? Esperion intends to find out
Stat
Esperion Therapeutics
cholesterol
Serometrix
Flag link:
FDA Refuses to Approve Novartis' $9.7 Billion Cholesterol Drug for Now
FDA Refuses to Approve Novartis' $9.7 Billion Cholesterol Drug for Now
Motley Fool
Novartis
FDA
cholesterol
inclisiran
complete response letter
Flag link:
Novartis’s big wager on RNAi approaches the finish line
Novartis’s big wager on RNAi approaches the finish line
EP Vantage
Novartis
RNAi
COVID-19
Leqvio
cholesterol
Flag link:
Ionis and Akcea announce that Pfizer initiated clinical study of vupanorsen
Ionis and Akcea announce that Pfizer initiated clinical study of vupanorsen
Pharmaceutical Business Review
Ionis Pharmaceuticals
Akcea Therapeutics
Pfizer
clinical trials
vupanorsen
cholesterol
Flag link:
AZ buys oral PCSK9 cholesterol drug from Dogma Therapeutics
AZ buys oral PCSK9 cholesterol drug from Dogma Therapeutics
Pharmaforum
AstraZeneca
Dogma Therapeutics
cholesterol
PCSK9 inhibitors
Flag link:
ESC: Amgen chases pediatric use for cholesterol-busting PCSK9 med Repatha
ESC: Amgen chases pediatric use for cholesterol-busting PCSK9 med Repatha
Fierce Pharma
ESC
Amgen
Repatha
Sanofi
Regeneron
Praluent
cholesterol
Flag link:
In its first tough test, CRISPR base editing slashes cholesterol levels in monkeys
In its first tough test, CRISPR base editing slashes cholesterol levels in monkeys
Stat
CRISPR
Verve Therapeutics
stem cells
cholesterol
Flag link:
Esperion strikes Japan deal for 'goldilocks' cholestrol drug, bags $60M cash as pandemic forces virtual US rollout
Esperion strikes Japan deal for 'goldilocks' cholestrol drug, bags $60M cash as pandemic forces virtual US rollout
Endpoints
Esperion
Nexletol
Nexlizet
Japan
cholesterol
Flag link:
Esperion adds more competition to cholesterol drug market with newly approved drug
Esperion adds more competition to cholesterol drug market with newly approved drug
BioPharma Dive
Esperion Therapeutics
cholesterol
bempedoic acid
FDA
Nexletol
Flag link:
Migraine, cholesterol upstarts top the list of FDA decisions to watch this quarter
Migraine, cholesterol upstarts top the list of FDA decisions to watch this quarter
Fierce Pharma
FDA
migraines
cholesterol
Epizyme
tazemetostat
Esperion
bempedoic acid
teprotumumab
Horizon Therapeutics
Biohaven
rimegepant
Flag link:

Pages